ARS Pharmaceuticals Future Growth
Future criteria checks 2/6
ARS Pharmaceuticals is forecast to grow earnings and revenue by 51.1% and 60.5% per annum respectively while EPS is expected to grow by 51.3% per annum.
Key information
51.1%
Earnings growth rate
51.3%
EPS growth rate
| Biotechs earnings growth | 28.8% |
| Revenue growth rate | 60.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 26 Sep 2024 |
Recent future growth updates
Recent updates
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 171 | -24 | -74 | -63 | 4 |
| 12/31/2025 | 58 | -90 | -117 | -67 | 4 |
| 12/31/2024 | 5 | -65 | -58 | -48 | 4 |
| 6/30/2024 | 1 | -45 | -44 | -44 | N/A |
| 3/31/2024 | 0 | -50 | -54 | -54 | N/A |
| 12/31/2023 | 0 | -54 | -59 | -59 | N/A |
| 9/30/2023 | 0 | -62 | -63 | -62 | N/A |
| 6/30/2023 | 0 | -53 | -56 | -55 | N/A |
| 3/31/2023 | 1 | -42 | -46 | -46 | N/A |
| 12/31/2022 | 1 | -35 | -40 | -40 | N/A |
| 9/30/2022 | 2 | -25 | -25 | -25 | N/A |
| 6/30/2022 | 2 | -25 | -24 | -24 | N/A |
| 3/31/2022 | 4 | -23 | -21 | -21 | N/A |
| 12/31/2021 | 6 | -20 | -18 | -18 | N/A |
| 12/31/2020 | 18 | -1 | 9 | 9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPRY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SPRY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SPRY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SPRY's revenue (60.5% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: SPRY's revenue (60.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPRY's Return on Equity is forecast to be high in 3 years time